M1A.2591 Drug-induced chronic gout, unspecified hip, with tophus (tophi)

Name of the Condition

• Drug-Induced Chronic Gout, Unspecified Hip, with Tophus (tophi)

Summary

Drug-induced chronic gout, unspecified hip, with tophus (tophi) is a form of arthritis affecting the hip joint, resulting from prolonged elevated uric acid levels due to medication use. It leads to recurrent joint inflammation and potential tissue damage, characterized by persistent symptoms and the presence of tophi (urate crystal deposits) in the affected area.

Causes

This condition arises from medications that interfere with uric acid metabolism or excretion, causing accumulation in the blood. Over time, urate crystals deposit in the hip joint and surrounding tissues, triggering inflammation. Common culprits include diuretics, low-dose aspirin, and certain chemotherapy agents.

Risk Factors

• Use of medications that increase uric acid levels (e.g., diuretics, low-dose aspirin)
• Prolonged exposure to urate-raising drugs
• Pre-existing hyperuricemia or gout history
• Renal impairment affecting drug clearance

Symptoms

• Recurrent episodes of intense hip pain, often with swelling and redness
• Persistent warmth and tenderness in the affected hip
• Formation of tophi (hard, painless lumps) around the hip joint
• Stiffness and limited range of motion in the hip
• Flare-ups triggered by stress, diet, or illness

Diagnosis

Diagnosis involves clinical evaluation, laboratory tests, and imaging. Blood tests assess uric acid levels, while joint fluid analysis may identify urate crystals. Imaging, such as X-rays or ultrasound, can detect tophi or joint damage. Clinical history of medication use and symptom patterns supports the diagnosis.

Treatment Options

Treatment focuses on reducing uric acid levels, managing pain, and preventing further joint damage. Medications may include urate-lowering agents (e.g., allopurinol) and anti-inflammatory drugs. In some cases, tophi may require surgical removal if they cause functional impairment or complications.

Prognosis and Follow-Up

With proper management, symptoms can be controlled, and joint damage may be slowed. Regular follow-up is essential to monitor uric acid levels, adjust medications, and assess for complications. Untreated or poorly managed cases may lead to progressive joint damage and disability.

Complications

• Chronic joint damage or deformity
• Persistent pain and reduced mobility
• Infection of tophi
• Kidney stones or renal impairment from uric acid buildup

Lifestyle & Prevention

• Avoid medications known to raise uric acid levels when possible.
• Maintain a balanced diet low in purines (e.g., limit red meat, seafood).
• Stay hydrated to support uric acid excretion.
• Follow prescribed treatment plans consistently.

When to Seek Professional Help

Seek medical attention if you experience severe or worsening hip pain, swelling, or stiffness, or if tophi become painful, infected, or increase in size. Prompt evaluation is important to prevent complications.

Tips for Medical Coders

This code (M1A.2591) is specific to drug-induced chronic gout affecting the unspecified hip with tophus. Ensure documentation confirms the hip involvement, the presence of tophi, and the drug-induced etiology. Code assignment requires clear clinical correlation between medication use, hip symptoms, and tophus formation.